Fly News Breaks for May 10, 2019
May 10, 2019 | 07:29 EDT
Canaccord analyst John Newman lowered his price target for Aldeyra to $20 from $35 and maintained a Buy rating, saying Aldeyra has enrolled the first patient in the critical Phase 3 dry eye study for reproxalap, testing the 0.25% dose. Newman says he lowered this price target based on more conservative launch timelines, and says he is conservatively assuming launch of reproxalap in 2022 for all indications, some of which may occur sooner.
News For ALDX From the Last 2 Days
There are no results for your query ALDX